FDA grants breakthrough therapy designation to Epstein-Barr virus targeted T-cells
Atara Biotherapeutics announced its collaborative partner, Memorial Sloan Kettering Cancer Center has received breakthrough therapy designation from the FDA for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus in treatment of patients with rituximab-refractory, EBV-LPD. March 02, 2015